Drug Development
Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in achondroplasia, Truist Securities analysts said Thursday.
FEATURED STORIES
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The Centers for Disease Control recommends wearing a mask in health care settings and other places where people around may have risk factors for severe consequences of COVID-19.
Pfizer has reported that an Omicron-specific vaccine will be available in March, should it be necessary. For those and more COVID-19 news, continue reading.
Sarepta Therapeutics shared positive topline results from its ongoing SRP-9001-102 study on the effectiveness of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy.
Another drug Vounatsos heralded was zuranolone, which Biogen is developing with Sage Therapeutics for multiple forms of depression.
Allogene announced that the chromosomal abnormality was not detected in any manufactured AlloCAR T product or any patient treated with the same lot of drugs.
Sigyn is not only trying to treat the inflammatory mediators that fuel sepsis; it wants to prevent the life-threatening event from occurring altogether.
The approval was based on data from a broad clinical program of 1,854 adults with insomnia conducted at more than 160 clinical sites in 18 countries.
The U.S. averages more than 700,000 new COVID-19 cases per day. As of Saturday, there were 4.91M cases, more cases in seven days than in April, May, June, and July 2021 combined.
Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.
The results over the two-year evaluation period for its Phase III GENEr8-1 trial showed consistent clinical benefit from using valoctocogene roxaparvovec.